Related Experiment Video

Updated: May 4, 2026

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

6.3K

NOTCH4 is a potential therapeutic target for triple-negative breast cancer

Iori Nagamatsu1, Hideya Onishi, Shojiro Matsushita

  • 1Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. ohnishi@surg1.med.kyushu-u.ac.jp.

Anticancer Research
|January 10, 2014
PubMed
Abstract

Insights

NOTCH4 receptor is a promising therapeutic target for triple-negative breast cancer (TNBC). Inhibiting NOTCH4 reduced cancer cell growth and spread, suggesting its potential in TNBC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Triple-negative breast cancer (TNBC) presents a significant clinical challenge due to its poor prognosis.
  • Identifying novel therapeutic targets is crucial for improving outcomes in TNBC patients.

Purpose of the Study:

  • To investigate the role of the NOTCH4 receptor as a potential therapeutic target in TNBC.
  • To evaluate the impact of NOTCH4 modulation on TNBC cell behavior and tumor growth.

Main Methods:

  • In vitro studies assessed TNBC cell proliferation and invasiveness following NOTCH4 inhibition (siRNA) or overexpression (plasmid transfection).
  • In vivo experiments involved subcutaneous implantation of MDA-MB-231 cells (with or without NOTCH4 siRNA) in mice to evaluate tumor growth.
  • Immunohistochemistry was used to determine the frequency of NOTCH4 nuclear translocation in clinical TNBC and non-TNBC samples.

Main Results:

  • NOTCH4 inhibition significantly decreased proliferation and invasiveness of TNBC cells in vitro.
  • NOTCH4 overexpression led to increased proliferation and invasiveness of TNBC cells.
  • NOTCH4 inhibition reduced tumor volume and tumorigenicity in mouse xenograft models.
  • TNBC samples exhibited a higher frequency of NOTCH4 nuclear translocation compared to non-TNBC samples.

Conclusions:

  • NOTCH4 plays a critical role in the progression of triple-negative breast cancer.
  • NOTCH4 represents a novel and promising therapeutic target for TNBC treatment.
Keywords:
NOTCH4Triple-negative breast cancerbreast cancerinvasionproliferationtherapeutic target

More Related Videos

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.8K
Stimulation of Notch Signaling in Mouse Osteoclast Precursors08:01

Stimulation of Notch Signaling in Mouse Osteoclast Precursors

Published on: February 28, 2017

7.7K

Related Concept Videos

Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
4.6K
Notch Signaling Pathway03:14

Notch Signaling Pathway

4.9K
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
1.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K